What Do The Three Biggest Gene Editing Stocks Do?
Some great memes have been flying around lately about how the already ignorant Robinhood lot is becoming even more ignorant, eating up just about anything you’ll feed it. A group of stock manipulators on Reddit are, well, manipulating the markets, and everyone pretends like it’s the second coming of Occupy Wall Street that’s overthrowing the man. “In my three days of trading, I’ve never seen anything like this,” one fellow remarked, and he’s right. Today, your best bet is to stay clear of the hype. If you get caught up in it, act rationally.
That’s what we told ourselves when our long positions in the three original gangstas of gene editing – CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics – soared to the moon and we decided to start trimming.
| Company | Ticker | Market Cap (billions) | 2019 Revenues (millions) |
| CRISPR | CRSP | $12.6 | $289 |
| Editas | EDIT | $4.1 | $21 |
| Intellia |
